Biosimilar Newsletter Archive

  1. 10.08.26 -- Building Trust In AI For Computerized System Validation 10/8/2026
    10/08/26
  2. 10.01.26 -- Faster Paths To Biosimilar Equivalence 10/1/2026

    10/01/26 Biosimilar Development Newsletter

  3. 09.24.26 -- Navigating The Regulatory Space To Biosimilar Approval 9/24/2026

    09/24/26 Biosimilar Development Newsletter

  4. 09.17.26 -- Your Collaborator: mAb Productivity And Robustness 9/17/2026

    09/17/26 Biosimilar Development Newsletter

  5. 09.17.26 -- A Much-Improved Approach For Managing Safety Risks 9/17/2026

    09/17/26 Biosimilar Development Newsletter

  6. 09.16.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises 9/16/2026

    09/16/26 Biosimilar Development Newsletter

  7. 09.10.26 -- U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 9/10/2026

    09/10/26 Biosimilar Development Newsletter

  8. 09.03.26 -- Why Trusted Data Is A Process Variable in Bioprocessing 9/3/2026

    09/03/26 Biosimilar Development Newsletter

  9. 08.27.26 -- The Missing Piece In Biosimilar Adoption 8/27/2026
    08/27/26 Biosimilar Development Newsletter
  10. 08.20.26 -- Exploring Takeda's Template For Sustainable Steam Generation 8/20/2026
    08/20/26 Biosimilar Development Newsletter